We read with great interest the article recently published in the American Journal of Neuroradiology by Barreras et al1 entitled, “Analysis of 30 Spinal Angiograms Falsely Reported as Normal in 18 Patients with Subsequently Documented Spinal Vascular Malformations.” This very valuable article for the interventional neuroradiology and neurosurgical communities presents the causes of false-negative digital subtraction angiography findings for the depiction of spinal dural arteriovenous fistulas (SDAVFs). The authors found that the most frequent reason for missing a SDAVF on spinal DSA (sDSA) was misinterpretation of abnormal findings documented on the DSA (55.6%), followed by nonexploration of the ROI (29.6%), and, finally, inadequate opacification of the artery supplying the fistula (nonselective injection) (14.8%).
We congratulate the authors for their effort in seeking the reasons for false-negative DSA findings in the diagnosis of SDAVF and for emphasizing the need for a rigorous protocol for spinal DSA. While spinal DSA is the criterion standard examination for the diagnosis of SDAVF,2 it remains an operator-dependent examination, which can lead to false-negative results in a substantial number of cases due to potentially avoidable operator-related misinterpretations. Missing a SDAVF on DSA has a great impact on a patient's outcome because it may delay the treatment, thus reducing the chance of recovery.
In addition to the recommendations suggested by the authors (adoption of rigorous technical and training standards and second opinion reviews), we would like to share our experience and insist on the need for full spinal DSA, which includes systematically (from top to bottom and bilaterally) the following: costocervical trunks, vertebral arteries, intercostal arteries, lumbar arteries, medial sacral artery, iliolumbar arteries, and lateral sacral arteries (superior and inferior). We insist that all these arteries must be catheterized as selectively as possible. For instance, for the lateral sacral arteries, the catheterization of the internal iliac artery is not sufficient because proximal injection may lead to poor opacification of the lateral sacral arteries (Fig 1). In the article of Barreras et al,1 most of the missed fistulas (52.9%) were at or below the L4 level, which confirms the need for a complete spinal DSA, including the lower spinal supplies.
Additionally, a cervical myelopathy may be observed in the case of an intracranial AVF with perimedullary venous drainage.3 Thus, a cerebral DSA with internal and external carotid artery catheterization and opacification should be performed secondarily in case of a negative sDSA finding.
In most cases of missed SDAVFs in the article of Barreras et al,1 the fistula was documented on the DSA but misinterpreted. Some conditions may enhance the quality of the images acquired during the sDSA, such as the intravenous injection of hyoscine or glucagon to reduce peristalsis-related artifacts or performing the sDSA with the patient under general anesthesia with provoked apnea during the runs to reduce the patient's motion artifacts.
A peculiar anatomic variation may also be responsible for a false-negative sDSA performed for SDAVF: a separate origin of the dorsospinal branch from the segmental artery on the aorta.4 Indeed, the dorsospinal branch (which usually gives rise to the radiculomeningeal branches) may not arise from the segmental artery but instead originate from the aorta. This anatomic variation can be suspected when no physiologic blush of the vertebral body is seen during the selective injection of the segmental artery (because the branches feeding the ipsilateral hemivertebral body are supplied by the dorsospinal trunk).
Furthermore, the catheterization of the origin of the segmental artery may be responsible for vasospasm. In case of a low-flow fistula, this spasm may reduce the flow toward the fistula, which could be responsible for the nonvisualization of the SDAVF.
Moreover, we stress that metachronous double dural AVFs,5 even if rare, may be observed. Thus, clinical recurrence after SDAVF treatment with negative sDSA findings at the SDAVF site should suggest performing a complete sDSA, looking for a second fistula.
Finally, the authors do not mention the potential of noninvasive/semi-invasive techniques such as time-resolved MR angiography6 or intra-aortic CT angiography (IA-CTA).7 These techniques potentially provide an overall examination of the whole spinal cord supply in a single acquisition. They may be valuable in patients with atheromatous vessels with stenosis at the origin of the intercostal/lumbar arteries, leading to difficult stable catheterization and thus to poor vessel opacification (Fig 2). However, while time-resolved MRA is sensitive for the depiction of SDAVFs (sensitivity as high as 81%6), the spatial resolution of this examination is limited and the precise location of the shunt point cannot be evaluated on time-resolved MRA in some cases.8 Concerning IA-CTA, despite its potential for the depiction of SDAVFs (sensitivity of 90%7) and the valuable information it provides regarding the location of the shunt point and its relationship with the bone landmarks, this examination may also provide false-negative results, mainly for SDAVFs supplied by branches from the internal iliac arteries, due to the incomplete opacification of the latter vessels by the contrast material injected directly in the aorta (Fig 1).
In conclusion, interventional neuroradiologists and neurologists should keep in mind that a single negative spinal DSA finding is not enough to rule out a spinal vascular malformation and therefore should be repeated with enhanced acquisition protocol if the clinical presentation is strongly suggestive of a SDAVF.
Footnotes
Disclosures: Frédéric Clarençon—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Balt Extrusion, Medtronic. David Grabli—UNRELATED: Board Membership: AbbVie, Zambon; Employment: Assistance Publique-Hôpitaux de Paris; Grants/Grants Pending: Assistance Publique-Hôpitaux de Paris, Institut National de la Santé et de la Recherche Medicable, France Parkinson*; Payment for Lectures Including Service on Speakers Bureaus: Novartis, Merz, Pharma AbbVie, Teva; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: AbbVie, Merz Pharma. Nader-Antoine Sourour—UNRELATED: Consultancy: Medtronic, MicroVention; Stock/Stock Options: Medina. *Money paid to the institution.
References
- © 2018 by American Journal of Neuroradiology